title: Clinical Outlook for Type-1 and FOXP3(+) T Regulatory Cell-Based Therapy.
abstract: T regulatory cells (Tregs) are subsets of T lymphocytes specialized in modulating antigen-specific immune responses in vivo. Hence, Tregs represent an ideal therapeutic tool to control detrimental immune reactions. Based on solid pre-clinical results, investigators started testing the safety and efficacy of Treg-based therapies in humans. Despite promising results, a number of issues remain to be solved. We will discuss the results obtained from clinical trials and the challenges and risks we are facing in the further development of Treg-based therapies.
authors.affiliation: Division of Regenerative Medicine, Stem Cells and Gene Therapy, IRCCS San Raffaele Scientific Institute, San Raffaele Telethon Institute for Gene Therapy (TIGET) , Milan , Italy.
authors.forename: Silvia
authors.initials: S
authors.lastname: Gregori
authors.affiliation: Division of Regenerative Medicine, Stem Cells and Gene Therapy, IRCCS San Raffaele Scientific Institute, San Raffaele Telethon Institute for Gene Therapy (TIGET) , Milan , Italy.
authors.forename: Laura
authors.initials: L
authors.lastname: Passerini
authors.affiliation: Department of Pediatric Stem Cell Transplantation and Regenerative Medicine, Stanford School of Medicine , Palo Alto, CA , USA.
authors.forename: Maria-Grazia
authors.initials: MG
authors.lastname: Roncarolo
keywords: FOXP3; IL-10; T regulatory cells; T regulatory type 1 cells; Treg-based therapy; gene transfer; tolerance